A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-Agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer

Trial Profile

A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-Agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2015

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLD
  • Most Recent Events

    • 05 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Dec 2014 United Kingdom Clinical Research Network record reports planned patient no as 2168.
    • 05 Dec 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top